AT
ATTBF.US Abattis Bioceuticals Corp
- Market cap
- USD 14.3K
- P/E
- -
- P/B
- 0.38x
- ROE
- -27.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Sep 2019.
Is ATTBF.US undervalued?
Graham numberThe Graham number of Abattis Bioceuticals Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Abattis Bioceuticals Corp fundamental analysis
No fundamental analysis for Abattis Bioceuticals Corp yet.
Abattis Bioceuticals Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Abattis Bioceuticals Corp
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation an…
Full company profileAbattis Bioceuticals Corp financial statements
Abattis Bioceuticals Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | - | 17.4K | 7.72K | 91.9K | 0.00 | 0.00 | 8.37K | 357K |
| Gross Profit | - | - | - | 5.64K | 7.72K | 62.6K | 0.00 | 0.00 | 6.48K | 241K |
| Operating Income | -759K | -1.61M | -1.01M | -1.03M | -7.36M | -3.08M | -2.31M | -6.36M | -17.4M | -3.96M |
| EBITDA | -564K | -1.58M | -966K | -1.00M | -7.27M | -3.17M | -2.13M | -5.34M | -17.3M | -2.90M |
| Net Income | -759K | -1.42M | -992K | -1.10M | -7.57M | -4.47M | -2.34M | -7.63M | -78.0M | -3.04M |
| EPS | -0.15 | -0.14 | -0.09 | -0.04 | -0.16 | -0.06 | -0.02 | -0.05 | -0.24 | -0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 813K | 718K | 1.33M | 1.63M | 5.90M | 1.61M | 1.27M | 1.21M | 11.4M | 19.3M |
| Total Liabilities | 433K | 127K | 702K | 1.07M | 1.26M | 1.14M | 1.06M | 439K | 303K | 8.59M |
| Shareholders' Equity | 380K | 591K | 623K | 558K | 4.04M | 861K | 671K | 1.52M | 11.5M | 11.1M |
| Cash & Short-term Investments | 349K | 5.87K | 5.50K | 5.33K | 1.36M | 258K | 38.5K | 526K | 9.10M | 2.40M |
| Total Debt | - | - | 158K | 597K | - | - | 30.9K | - | - | 1.57M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -325K | -486K | -252K | -230K | -2.11M | -1.82M | -733K | -1.22M | -8.28M | 9.41M |
| Capital Expenditure | 0.00 | 2.05K | 84.2K | 0.00 | 465K | 146K | 45.7K | 431K | 234K | 5.06M |
| Free Cash Flow | -325K | -488K | -336K | -230K | -2.57M | -1.97M | -779K | -1.65M | -8.51M | 4.35M |
| Ratios | ||||||||||
| ROE | -199.8% | -240.1% | -159.2% | -197.6% | -187.2% | -519.7% | -348.7% | -500.7% | -679.1% | -27.5% |
| ROA | -93.4% | -197.5% | -74.9% | -67.7% | -128.2% | -277.2% | -184.6% | -630.5% | -684.4% | -15.8% |
| Net Profit Margin | - | - | - | -6,318.7% | -98,049.4% | -4,864.6% | - | - | -931,940.1% | -852.4% |
| Debt to Equity | - | - | 0.25x | 1.07x | - | - | 0.05x | - | - | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Abattis Bioceuticals Corp dividends
Abattis Bioceuticals Corp has not paid dividends in the last 10 fiscal years.
Last stock split: 1:5 on Sep 11, 2012.
Who owns Abattis Bioceuticals Corp
Ownership data of Abattis Bioceuticals Corp is not available yet.
Abattis Bioceuticals Corp company profile
- Company name
- Abattis Bioceuticals Corp
- Ticker
- ATTBF.US
- ISIN
- CA00258G1037
- Exchange
- USA Stocks
- Listed since
- Feb 11, 1999
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- September
- Address
- 625 Howe Street, Vancouver, BC, Canada, V6C 2M6
- Phone
- 808 650 3007
- Website
- abattis.com
About Abattis Bioceuticals Corp
Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.
Abattis Bioceuticals Corp management
6- Mr. Francesco PaoliniCFO & Director
- Mr. Patrick MitchellCOO & Director
- Mr. Shawn BalaghiHead of Corporate Development
- Mr. Jim CarterHead of Mergers and Acquisitions Advisory
- Mr. Christopher P. Cherry C.A., CPA, CGACorporate Comptroller · born 1979
- Ms. Nicole BreitingerCorporate Secretary